Warby Parker Inc. (WRBY) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 3.80%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 3.80% | Share-based compensation / revenue. Period ending 2026-06-30. $34.60M ÷ $911.61M × 100 ≈ 3.80% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 911.61M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 34.60M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 1.55M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $911.61M | $34.60M | $1.55M | (m) | (m) | 3.80% | (m) | (m) |
| 2026-03-31 | (m) | $890.57M | $33.59M | $-6.14M | (m) | (m) | 3.77% | (m) | (m) |
| 2025-12-31 | (m) | $871.90M | $34.54M | $-5.34M | (m) | (m) | 3.96% | (m) | (m) |
| 2025-09-30 | (m) | $850.58M | $36.89M | $-7.90M | (m) | (m) | 4.34% | (m) | (m) |
| 2025-06-30 | (m) | $821.35M | $40.64M | $-18.08M | (m) | (m) | 4.95% | (m) | (m) |
| 2025-03-31 | (m) | $795.09M | $45.58M | $-22.51M | (m) | (m) | 5.73% | (m) | (m) |
| 2024-12-31 | (m) | $771.32M | $47.29M | $-30.11M | (m) | (m) | 6.13% | (m) | (m) |
| 2024-09-30 | (m) | $742.53M | $55.09M | $-42.27M | (m) | (m) | 7.42% | (m) | (m) |
| 2024-06-30 | (m) | $719.93M | $60.60M | $-55.42M | (m) | (m) | 8.42% | (m) | (m) |
| 2024-03-31 | (m) | $697.80M | $64.78M | $-64.69M | (m) | (m) | 9.28% | (m) | (m) |
| 2023-12-31 | (m) | $669.76M | $70.51M | $-72.00M | (m) | (m) | 10.53% | (m) | (m) |
| 2023-09-30 | (m) | $654.40M | $73.91M | $-72.14M | (m) | (m) | 11.29% | (m) | (m) |
| 2023-06-30 | (m) | $633.33M | $81.92M | $-76.04M | (m) | (m) | 12.93% | (m) | (m) |
| 2023-03-31 | (m) | $616.86M | $90.67M | $-89.89M | (m) | (m) | 14.70% | (m) | (m) |
| 2022-12-31 | (m) | $598.11M | $98.03M | $-111.20M | (m) | (m) | 16.39% | (m) | (m) |
| 2022-09-30 | (m) | $584.51M | $109.36M | $-135.39M | (m) | (m) | 18.71% | (m) | (m) |
| 2022-06-30 | (m) | $573.11M | $149.39M | $-203.69M | (m) | (m) | 26.07% | (m) | (m) |
| 2022-03-31 | (m) | $555.04M | $133.03M | $-180.42M | (m) | (m) | 23.97% | (m) | (m) |
| 2021-12-31 | (m) | $540.80M | $107.15M | $-143.66M | (m) | (m) | 19.81% | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $393.72M | $44.91M | $-55.63M | (m) | (m) | 11.41% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $370.46M | $8.50M | $-1.66M | (m) | (m) | 2.29% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| National Vision Holdings, Inc. (EYE) | United States | $1.297B | |
| STAAR SURGICAL CO (STAA) | United States | $0.957B | 362.70 |
| RxSight, Inc. (RXST) | United States | $0.197B | |
| Innovative Eyewear Inc (LUCY) | United States | $0.008B | |
| Bausch & Lomb Corp (BLCO) | Canada | $6.008B | -34.58 |
| COOPER COMPANIES, INC. (COO) | United States | $10.533B | 24.09 |